GleamWall
中文EN

STRO SUTRO BIOPHARMA, INC.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1382101 · Fiscal year ends 12/31

Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-34.4%
TTM net income YoY-74.9%
TTM EPS YoY-2,761.9%
Revenue 3-yr CAGR14.8%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-175.7%
Net margin-205.2%
FCF margin—
EBITDA margin-168.5%

Returns

ROE-1,810.0%
ROA-65.5%
ROIC (approx.)—
Asset turnover0.32x

Leverage & solvency

Liabilities / assets141.6%
Debt / equity—
Current ratio2.53x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.03x
Accruals ratio1.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$102.48M$62.04M$153.73M$67.77M$61.88M
R&D expense$166.42M$252.04M$180.43M$137.17M$104.40M
SG&A expense$41.02M$48.45M$62.58M$59.54M$56.00M
Operating income-$158.37M-$238.45M-$89.28M-$128.94M-$98.52M
Interest expense——$1.30M$2.40M$2.60M
Pretax income-$191.18M-$225.10M-$88.60M-$116.70M-$105.54M
Income tax-$93,000$2.36M$18.19M$2.50M$0
Net income-$191.09M-$227.46M-$106.79M-$119.20M-$105.54M
EBITDA-$151.04M-$231.24M-$82.46M-$123.25M-$93.68M
EPS (basic)-22.49-29.40-1.78-2.35-2.29
EPS (diluted)-22.49-29.40-1.78-2.35-2.29
Weighted avg. shares (diluted)8.50M7.74M60.16M50.74M46.12M
Balance sheet
Cash & equivalents$58.13M$190.30M$69.27M$47.25M$30.41M
Short-term investments$83.30M$126.59M$264.41M$255.09M$130.34M
Receivables$3.98M$8.62M$36.08M$7.12M$12.45M
Current assets$150.93M$343.31M$421.54M$353.15M$218.51M
PP&E, net$10.65M$18.19M$21.94M$24.62M$22.55M
Total assets$173.83M$387.21M$470.74M$406.94M$341.41M
Current liabilities$75.13M$131.89M$93.75M$66.55M$41.74M
Short-term debt——$4.06M$12.50M$9.38M
Long-term debt——$0$3.77M$15.74M
Total debt——$4.06M$16.27M$25.11M
Total liabilities$306.28M$342.61M$321.09M$189.90M$88.84M
Shareholders' equity-$132.45M$44.60M$149.65M$217.05M$252.56M
Net debt——-$65.21M-$30.98M-$5.30M
Shares outstanding8.58M8.31M61.01M57.50M46.33M
Cash flow statement
Operating cash flow-$177.23M-$191.54M-$111.62M$3.55M-$81.68M
Investing cash flow$45.01M$218.51M-$3.92M-$35.02M-$97.31M
Financing cash flow$44,000$94.05M$137.55M$48.31M$3.26M
Depreciation & amortization$7.32M$7.22M$6.82M$5.69M$4.84M
Stock-based compensation$14.01M$24.69M$24.91M$26.30M$23.24M
Share buybacks————$7,000

Free plan shows the latest 5 periods; Pro shows all 10 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.